|
nasdaq:edit
|
https://www.indeed.com/cmp/editas-medicine
|
Aug 29th, 2022 12:00AM
|
Open
|
Editas Medicine
|
|
Pharmaceutical & Biotechnology
|
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Our goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer.
We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
Mission: Our mission is to translate the power and potential of genome editing into a broad class of gene edited medicines that transform lives of people living with serious diseases.
|
RRv1_25M_100M
|
Cambridge, MA
|
Gilmore O'Neill
|
|
|
2.70
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.00
|
3.00
|
2.00
|
4.30
|
2.00
|
2.70
|
3.30
|
|
|
|
|
5.00
|
AVERAGE
|
|
|
|
Aug 29th, 2022 11:54AM
|
Aug 29th, 2022 11:54AM
|
Editas Medicine
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:edit
|
https://www.indeed.com/cmp/editas-medicine
|
Aug 28th, 2022 12:00AM
|
Open
|
Editas Medicine
|
|
Pharmaceutical & Biotechnology
|
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Our goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer.
We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
Mission: Our mission is to translate the power and potential of genome editing into a broad class of gene edited medicines that transform lives of people living with serious diseases.
|
RRv1_25M_100M
|
Cambridge, MA
|
Gilmore O'Neill
|
|
|
2.70
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.00
|
3.00
|
2.00
|
4.30
|
2.00
|
2.70
|
3.30
|
|
|
|
|
5.00
|
AVERAGE
|
|
|
|
Aug 28th, 2022 04:53AM
|
Aug 28th, 2022 04:53AM
|
Editas Medicine
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:edit
|
https://www.indeed.com/cmp/editas-medicine
|
Aug 27th, 2022 12:00AM
|
Open
|
Editas Medicine
|
|
Pharmaceutical & Biotechnology
|
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Our goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer.
We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
Mission: Our mission is to translate the power and potential of genome editing into a broad class of gene edited medicines that transform lives of people living with serious diseases.
|
RRv1_25M_100M
|
Cambridge, MA
|
Gilmore O'Neill
|
|
|
2.70
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.00
|
3.00
|
2.00
|
4.30
|
2.00
|
2.70
|
3.30
|
|
|
|
|
5.00
|
AVERAGE
|
|
|
|
Aug 27th, 2022 04:12AM
|
Aug 27th, 2022 04:12AM
|
Editas Medicine
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:edit
|
https://www.indeed.com/cmp/editas-medicine
|
Aug 25th, 2022 12:00AM
|
Open
|
Editas Medicine
|
|
Pharmaceutical & Biotechnology
|
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Our goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer.
We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
Mission: Our mission is to translate the power and potential of genome editing into a broad class of gene edited medicines that transform lives of people living with serious diseases.
|
RRv1_25M_100M
|
Cambridge, MA
|
Gilmore O'Neill
|
|
|
2.70
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.00
|
3.00
|
2.00
|
4.30
|
2.00
|
2.70
|
3.30
|
|
|
|
|
5.00
|
AVERAGE
|
|
|
|
Aug 25th, 2022 08:52AM
|
Aug 25th, 2022 08:52AM
|
Editas Medicine
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:edit
|
https://www.indeed.com/cmp/editas-medicine
|
Aug 23rd, 2022 12:00AM
|
Open
|
Editas Medicine
|
|
Pharmaceutical & Biotechnology
|
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Our goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer.
We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
Mission: Our mission is to translate the power and potential of genome editing into a broad class of gene edited medicines that transform lives of people living with serious diseases.
|
RRv1_25M_100M
|
Cambridge, MA
|
Gilmore O'Neill
|
|
|
2.70
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.00
|
3.00
|
2.00
|
4.30
|
2.00
|
2.70
|
3.30
|
|
|
|
|
5.00
|
AVERAGE
|
|
|
|
Aug 23rd, 2022 10:45AM
|
Aug 23rd, 2022 10:45AM
|
Editas Medicine
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:edit
|
https://www.indeed.com/cmp/editas-medicine
|
Aug 21st, 2022 12:00AM
|
Open
|
Editas Medicine
|
|
Pharmaceutical & Biotechnology
|
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Our goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer.
We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
Mission: Our mission is to translate the power and potential of genome editing into a broad class of gene edited medicines that transform lives of people living with serious diseases.
|
RRv1_25M_100M
|
Cambridge, MA
|
Gilmore O'Neill
|
|
|
2.70
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.00
|
3.00
|
2.00
|
4.30
|
2.00
|
2.70
|
3.30
|
|
|
|
|
5.00
|
AVERAGE
|
|
|
|
Aug 21st, 2022 12:29PM
|
Aug 21st, 2022 12:29PM
|
Editas Medicine
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:edit
|
https://www.indeed.com/cmp/editas-medicine
|
Aug 20th, 2022 12:00AM
|
Open
|
Editas Medicine
|
|
Pharmaceutical & Biotechnology
|
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Our goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer.
We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
Mission: Our mission is to translate the power and potential of genome editing into a broad class of gene edited medicines that transform lives of people living with serious diseases.
|
RRv1_25M_100M
|
Cambridge, MA
|
Gilmore O'Neill
|
|
|
2.70
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.00
|
3.00
|
2.00
|
4.30
|
2.00
|
2.70
|
3.30
|
|
|
|
|
5.00
|
AVERAGE
|
|
|
|
Aug 20th, 2022 02:06PM
|
Aug 20th, 2022 02:06PM
|
Editas Medicine
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:edit
|
https://www.indeed.com/cmp/editas-medicine
|
Aug 19th, 2022 12:00AM
|
Open
|
Editas Medicine
|
|
Pharmaceutical & Biotechnology
|
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Our goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer.
We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
Mission: Our mission is to translate the power and potential of genome editing into a broad class of gene edited medicines that transform lives of people living with serious diseases.
|
RRv1_25M_100M
|
Cambridge, MA
|
Gilmore O'Neill
|
|
|
2.70
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.00
|
3.00
|
2.00
|
4.30
|
2.00
|
2.70
|
3.30
|
|
|
|
|
5.00
|
AVERAGE
|
|
|
|
Aug 19th, 2022 12:29PM
|
Aug 19th, 2022 12:29PM
|
Editas Medicine
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:edit
|
https://www.indeed.com/cmp/editas-medicine
|
Aug 18th, 2022 12:00AM
|
Open
|
Editas Medicine
|
|
Pharmaceutical & Biotechnology
|
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Our goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer.
We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
Mission: Our mission is to translate the power and potential of genome editing into a broad class of gene edited medicines that transform lives of people living with serious diseases.
|
RRv1_25M_100M
|
Cambridge, MA
|
Gilmore O'Neill
|
|
|
2.70
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.00
|
3.00
|
2.00
|
4.30
|
2.00
|
2.70
|
3.30
|
|
|
|
|
5.00
|
AVERAGE
|
|
|
|
Aug 18th, 2022 04:13AM
|
Aug 18th, 2022 04:13AM
|
Editas Medicine
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:edit
|
https://www.indeed.com/cmp/editas-medicine
|
Aug 17th, 2022 12:00AM
|
Open
|
Editas Medicine
|
|
Pharmaceutical & Biotechnology
|
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Our goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer.
We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
Mission: Our mission is to translate the power and potential of genome editing into a broad class of gene edited medicines that transform lives of people living with serious diseases.
|
RRv1_25M_100M
|
Cambridge, MA
|
Gilmore O'Neill
|
|
|
2.70
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.00
|
3.00
|
2.00
|
4.30
|
2.00
|
2.70
|
3.30
|
|
|
|
|
5.00
|
AVERAGE
|
|
|
|
Aug 17th, 2022 09:52AM
|
Aug 17th, 2022 09:52AM
|
Editas Medicine
|
Health Care
|
Pharmaceuticals & Biotechnology
|